{"<h3>Objectives</h3>": [0], "To": [1], "provide": [2, 307], "an": [3], "update": [4, 57], "of": [5, 39, 54, 73, 77, 89, 108, 171, 181, 217, 226, 240, 242, 291, 295], "the": [6, 14, 19, 55, 87, 143, 235, 257, 269], "EULAR": [7, 305], "rheumatoid": [8], "arthritis": [9], "(RA)": [10], "management": [11, 311], "recommendations": [12, 105, 306], "addressing": [13], "most": [15, 300], "recent": [16], "developments": [17], "in": [18, 52, 161, 253], "field.": [20], "<h3>Methods</h3>": [21], "An": [22], "international": [23], "task": [24, 96], "force": [25, 97], "was": [26, 50, 64], "formed": [27], "and": [28, 37, 44, 70, 75, 82, 103, 137, 159, 176, 179, 192, 293, 315], "solicited": [29], "three": [30], "systematic": [31], "literature": [32], "research": [33], "activities": [34], "on": [35, 86, 99, 152, 193, 206, 309], "safety": [36], "efficacy": [38], "disease-modifying": [40], "antirheumatic": [41], "drugs": [42], "(DMARDs)": [43], "glucocorticoids": [45], "(GCs).": [46], "The": [47, 95], "new": [48], "evidence": [49, 74, 292], "discussed": [51], "light": [53], "last": [56], "from": [58], "2019.": [59], "A": [60], "predefined": [61], "voting": [62], "process": [63], "applied": [65], "to": [66, 81, 196, 209, 234], "each": [67, 92], "overarching": [68, 101], "principle": [69], "recommendation.": [71], "Levels": [72, 290], "strengths": [76], "recommendation": [78], "were": [79, 183, 297], "assigned": [80], "participants": [83], "finally": [84], "voted": [85], "level": [88], "agreement": [90, 296], "with": [91], "item.": [93], "<h3>Results</h3>": [94], "agreed": [98], "5": [100], "principles": [102], "11": [104], "concerning": [106], "use": [107], "conventional": [109], "synthetic": [110, 139], "(cs)": [111], "DMARDs": [112, 120, 281], "(methotrexate": [113], "(MTX),": [114], "leflunomide,": [115], "sulfasalazine);": [116], "GCs;": [117], "biological": [118], "(b)": [119], "(tumour": [121], "necrosis": [122], "factor": [123], "inhibitors": [124, 146], "(adalimumab,": [125], "certolizumab": [126], "pegol,": [127], "etanercept,": [128], "golimumab,": [129], "infliximab": [130], "including": [131, 169, 312], "biosimilars),": [132], "abatacept,": [133], "rituximab,": [134], "tocilizumab,": [135], "sarilumab": [136], "targeted": [138], "(ts)": [140], "DMARDs,": [141], "namely": [142], "Janus": [144], "kinase": [145], "tofacitinib,": [147], "baricitinib,": [148], "filgotinib,": [149], "upadacitinib.": [150], "Guidance": [151], "monotherapy,": [153], "combination": [154], "therapy,": [155], "treatment": [156, 202], "strategies": [157], "(treat-to-target)": [158], "tapering": [160], "sustained": [162, 279], "clinical": [163], "remission": [164], "is": [165, 190, 276], "provided.": [166], "Safety": [167], "aspects,": [168], "risk": [170, 210], "major": [172], "cardiovascular": [173], "events": [174, 247], "(MACEs)": [175], "malignancies,": [177], "costs": [178], "sequencing": [180], "b/tsDMARDs": [182], "all": [184], "considered.": [185], "Initially,": [186], "MTX": [187], "plus": [188], "GCs": [189], "recommended": [191], "insufficient": [194], "response": [195], "this": [197, 254], "therapy": [198], "within": [199], "3\u20136": [200], "months,": [201], "should": [203, 231, 286], "be": [204, 232, 251, 283, 288], "based": [205], "stratification": [207], "according": [208], "factors;": [211], "With": [212, 278], "poor": [213], "prognostic": [214], "factors": [215], "(presence": [216], "autoantibodies,": [218], "high": [219, 298], "disease": [220], "activity,": [221], "early": [222], "erosions": [223], "or": [224, 268, 272], "failure": [225], "two": [227], "csDMARDs),": [228], "any": [229, 263], "bDMARD": [230, 259, 265], "added": [233], "csDMARD;": [236], "after": [237], "careful": [238], "consideration": [239], "risks": [241], "MACEs,": [243], "malignancies": [244], "and/or": [245], "thromboembolic": [246], "tsDMARDs": [248], "may": [249, 282], "also": [250], "considered": [252], "phase.": [255], "If": [256], "first": [258], "(or": [260], "tsDMARD)": [261], "fails,": [262], "other": [264], "(from": [266], "another": [267], "same": [270], "class)": [271], "tsDMARD": [273], "(considering": [274], "risks)": [275], "recommended.": [277], "remission,": [280], "tapered": [284], "but": [285], "not": [287], "stopped.": [289], "levels": [294], "for": [299], "recommendations.": [301], "<h3>Conclusions</h3>": [302], "These": [303], "updated": [304], "consensus": [308], "RA": [310], "safety,": [313], "effectiveness": [314], "cost.": [316]}